CardioVax

Industry Outlook

IONpath, Inc. | August 27, 2021

Ionpath, Inc., the leader in high-definition spatial proteomics, today announced a new program for biopharmaceutical research organizations interested in piloting spatial phenotyping analyses of tissue samples leveraging the company's Multiplexed Ion Beam Imaging (MIBI™) technology. Through this new program, customers can benefit from in-depth immune profiling and spatial analysis performed with the company's 30-marker Checkpoint Panel on its MIBIscope™ System. ...

Cell and Gene Therapy

Takeda | January 11, 2022

Takeda Pharmaceutical Company Limited announced the exercise of its option to acquire Adaptate Biotherapeutics a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells. Through the acquisition, Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate’s γδ T cell engagers are des...

Precision Virologics | September 23, 2020

Biotech startup Precision Virologics, which develops adenovirus-based vaccines in St. Louis, and Bharat Biotech, a vaccine manufacturing giant, jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets. The licensing agreements will lead to rapid clinical development, following the intranasal vaccine c...

Research

Samsung Biologics | July 21, 2021

Kineta, Inc., a clinical-stage biotech firm developing novel immunotherapies in oncology, has signed a strategic partnership agreement with Samsung Biologics, one of the world's top contract development and manufacturing companies (CDMO). To support the IND filing for KVA12.1, Kineta's new anti-VISTA antibody under development to treat solid tumors, Samsung Biologics will offer end-through-end CDMO services ranging from cell line development to cell line development clinical drug substan...